30 completed, 10 recruiting, 8 terminated, 2 active not recruiting. 20 Phase 2, 13 Phase 1, 12 Phase 3, 3 Not applicable.
Follow Chronic Inducible Urticaria: new trials by email Literature Review of Chronic Inducible Urticaria trials Research Report on Chronic Inducible Urticaria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Apremilast Added to Antihistamines in Chronic Urticaria Apremilast, Second-generation H1 antihistamine - Chronic Urticaria, Chronic Spontaneous Urticaria | Phase 2 | Enrolling by invitation | Rashid Latif Medical College | 86 | 2026-09-23 | 2026-09-30 |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults EDP-978, Placebo - Chronic Inducible Urticaria, Chronic Spontaneous Urticaria | Phase 1 | Recruiting | Enanta Pharmaceuticals, Inc | 98 | 2026-04-01 | 2026-04-21 |
| A Real-World Study of Omalizumab Treatment Patterns in Chronic Urticaria Patients in China Chronic Urticaria | Completed | Novartis Pharmaceuticals | 3485 | 2026-03-10 | 2026-04-15 | |
| Circadian Rhythm Deregulation in Patients With CAPS Genetic analysis of NLRP3, Circadian rhythm measurement, Saliva sampling - Cryopyrin Associated Periodic Syndrome, Familial Cold Urticaria | Not applicable | Recruiting | Hospices Civils de Lyon | 30 | 2026-02-25 | 2026-02-27 |
| Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS) JTE-162 - Cryopyrin-associated Periodic Syndromes (CAPS) | Phase 1 | Completed | Akros Pharma Inc. | 5 | 2026-02-02 | 2026-10-09 |
| A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD) Barzolvolimab, Matching Placebo - Chronic Inducible Urticaria, Cold Urticaria | Phase 3 | Recruiting | Celldex Therapeutics | 240 | 2026-01-15 | 2026-10-07 |
| A Phase 1 Study of GTX-B001 in Healthy Subjects and Patients With Chronic Inducible Urticaria GTX-B001, Normal Saline - Healthy Subjects, Cold Urticaria | Phase 1 | Recruiting | Granular Therapeutics Limited | 72 | 2025-10-06 | 2026-09-09 |
| Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load 124I AT-01 - Cryopyrin-Associated Periodic Syndromes, Amyloidosis | Phase 1 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 30 | 2025-09-10 | 2026-05-19 |
| Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU) BLU-808, Placebo - Chronic Inducible Urticaria, Chronic Spontaneous Urticaria | Phase 2 | Active not recruiting | Blueprint Medicines Corporation | 105 | 2025-05-28 | 2026-07-22 |
| Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria Remibrutinib, Placebo - Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU) | Phase 2 | Recruiting | Novartis Pharmaceuticals | 44 | 2025-05-22 | 2026-09-28 |
| Ilaris NIS in Korea Ilaris - Hereditary Periodic Fever Syndromes, Cryopyrin-associated Periodic Syndromes (CAPS) | Recruiting | Novartis Pharmaceuticals | 25 | 2025-03-29 | 2026-05-19 | |
| Deep Phenotyping of CIndU Skin Diseases, Angio-Oedema and/or Urticaria | Recruiting | Centre for Human Drug Research, Netherlands | 40 | 2025-01-21 | 2026-01-22 | |
| A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria Oral EVO756 300 mg QD, Oral EVO756 50 mg BID - Chronic Inducible Urticaria | Phase 2 | Completed | Evommune, Inc. | 30 | 2024-08-14 | 2026-05-19 |
| A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines Briquilimab - Chronic Inducible Urticaria | Phase 1 / Phase 2 | Terminated | Jasper Therapeutics, Inc. | 27 | 2024-03-18 | 2025-10-08 |
| A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines Remibrutinib, Placebo - Chronic Inducible Urticaria | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 362 | 2023-12-07 | 2026-10-15 |
| Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria Oral EP262 - Chronic Inducible Urticaria | Phase 1 | Completed | Escient Pharmaceuticals, Inc | 33 | 2023-08-30 | 2024-12-09 |
| A Single Dose, Phase 1 Study of YH35324 in Patients with Various Allergic Diseases YH35324, Omalizumab, Placebo - Allergic Disease, Chronic Spontaneous Urticaria | Phase 1 | Completed | Yuhan Corporation | 30 | 2023-08-23 | 2024-11-22 |
| A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome VTX2735 - Cryopyrin Associated Periodic Syndrome | Phase 2 | Completed | Zomagen Biosciences Ltd. | 7 | 2023-03-18 | 2025-03-10 |
| A Study of CDX-0159 in Patients With Chronic Inducible Urticaria barzolvolimab, Matching Placebo - Chronic Inducible Urticaria | Phase 2 | Completed | Celldex Therapeutics | 196 | 2022-06-28 | 2025-11-06 |
| A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZYIL1 in Subjects With Cryopyrin Associated Periodic Syndromes (CAPS) ZYIL1 capsule - Cryopyrin Associated Periodic Syndrome | Phase 2 | Completed | Zydus Lifesciences Limited | 3 | 2022-06-01 | 2022-07-11 |
Showing 20 of 55. Sign in to see all of them.
Cryopyrin-Associated Periodic Syndromes (35) · Chronic Urticaria (9) · Cold Urticaria (8) · Familial dermographism (7) · Multiple Pterygium Syndrome, Autosomal Dominant (5) · Urticaria (5) · Urticaria, Solar (4) · Skin Diseases (3) · Arthritis, Juvenile (2) · Mevalonate Kinase Deficiency (2) · Pruritus (2) · Amyloidosis (1) · Arthralgia (1) · Arthritis, Rheumatoid (1)
Chronic Disease (55) · Disease Attributes (55) · Hypersensitivity (55) · Pathologic Processes (55) · Pathological Conditions, Signs and Symptoms (55) · Skin and Connective Tissue Diseases (55) · Hypersensitivity, Immediate (54) · Immune System Diseases (54) · Skin Diseases, Vascular (54) · Skin Diseases (52) · Urticaria (50) · Chronic Urticaria (46) · Cold Urticaria (35) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (35)
canakinumab (10) · Interleukin 1 Receptor Antagonist Protein (4) · rilonacept (3) · Omalizumab (2) · ligelizumab (2) · remibrutinib (2) · BID protein, human (1) · Blood Specimen Collection (1) · Histamine H1 Antagonists, Non-Sedating (1) · Immunoglobulins, Intravenous (1) · Injections (1) · Saline Solution (1) · Surveys and Questionnaires (1) · Water (1) · ZYIL1 (1)
Novartis Pharmaceuticals (15) · Centre Hospitalier Universitaire de Besancon (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (3) · Celldex Therapeutics (2) · Handok Inc. (2) · Novartis (2) · Aclaris Therapeutics, Inc. (1) · Akros Pharma Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · Blueprint Medicines Corporation (1) · Centre for Human Drug Research, Netherlands (1) · Charite University, Berlin, Germany (1) · Clinuvel Pharmaceuticals Limited (1) · Enanta Pharmaceuticals, Inc (1)
United States (24) · Germany (17) · France (15) · Spain (12) · United Kingdom (9) · Canada (7) · South Korea (5) · Australia (4) · China (4) · India (4) · Italy (4) · Netherlands (4) · Poland (4) · Belgium (3) · Hungary (3)
Raphaela T Goldbach-Mansky, M.D. (2) · David Gordon (1) · Dr Deven Parmar, MD (1) · Eric Hachulla, MD,PhD (1) · Felix W Leung, MD (1) · Hae-Sim Park (1) · Henrik Sonnergren, MD, PhD (1) · Hirsh D Komarow, M.D. (1) · Hongmei Song (1) · Hyeong Ki Lee, Professor (1)
PMID 31161734, PMID 16899778, PMID 18668535, PMID 18668591, PMID 19494217, PMID 21356079, PMID 21859692, PMID 22152723, PMID 22294344, PMID 22583335, PMID 23031624, PMID 23380020, PMID 24906637, PMID 25223501, PMID 27143789, PMID 28118536, PMID 29134648, PMID 29638206, PMID 29649002, PMID 31874111, PMID 32252809, PMID 34001647, PMID 35289316
2023 (2), 2009 (1), 2014 (1), 2019 (1), 2025 (1), ZIAAR041138-08 (1)